For testing inflammatory responses
Epistem, a UK-based biotechnology and personalised medicine company has joined forces with Norwegian firm ScandiDerma to develop a new in vitro human living skin equivalent model for testing inflammatory responses.
The collaboration is made possible through the UK's Technology Strategy Board and Innovation Norway following a successful application for funding in the ‘Sustainable high value chemical manufacture through industrial biotechnology’ competition.
The project starts this month and runs to March 2014 and will take place at project leader Epistem's facilities in Manchester, UK and ScandiDerma's facilities in Barents Biocenter, Tromsø, Norway.
